COMP <GO>
ALGN vs ABBV // FREE CASH FLOW YIELD
Align Technology Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ALGN 5
— ABBV 9
▲ FREE CASH FLOW YIELD LEADER: ALGN
LAST: $149.89 (-2.49%) • MKT CAP: $10.92B
fcf-yield
4.49%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALGN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALGN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.20% | 70.20% | -3.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.10% | 29.00% | -17.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.0x | 33.3x | -16.30 | ALGN | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 4.49% | 3.47% | +1.02 | ALGN | /fcf-yield <GO> |
| Operating Margin | 13.50% | 24.60% | -11.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 10.20% | 6.90% | +3.30 | ALGN | /net-margins <GO> |
| Revenue Growth (YoY) | 0.90% | 8.60% | -7.70 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.62 | 5.33 | -0.71 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.40% | -0.80 | ALGN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 72.8 | -22.97 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 1.15 | -0.25 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.7x | 113.1x | -88.40 | ALGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.92B | $513.86B | -$502.94B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALGN REV | ABBV REV | ALGN GROSS % | ABBV GROSS % | ALGN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.03B | $61.16B | 67.2% | 70.2% | $490.8M | $17.82B |
| FY 2024 | $4.00B | $56.33B | 70.0% | 70.0% | $622.7M | $17.83B |
| FY 2023 | $3.86B | $54.32B | 44.0% | 44.0% | $612.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALGN // BETA 0.90
ABBV // BETA 1.15